{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T01:01:03Z","timestamp":1781053263378,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.leukres.2026.108239","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:50:46Z","timestamp":1777564246000},"page":"108239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world data on the use of asciminib in chronic-phase chronic myeloid leukemia after two or more prior tyrosine kinase inhibitors: Results of the Turkish managed access program along with a literature review"],"prefix":"10.1016","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7561-446X","authenticated-orcid":false,"given":"Deniz","family":"\u00d6zmen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya Deniz","family":"K\u00fcrek\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vildan","family":"\u00d6zkocaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"Alt\u0131nda\u011f Avc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis Sabriye","family":"Bozer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutlu","family":"Kasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fclten","family":"Korkmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9899-1441","authenticated-orcid":false,"given":"Ferda","family":"Can","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Sezgin","family":"Pepeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nergiz","family":"Erkut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7523-8599","authenticated-orcid":false,"given":"Onur","family":"K\u0131rk\u0131zlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00fcbra","family":"Yel Uygun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuba","family":"Bulduk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6416-9575","authenticated-orcid":false,"given":"Murat","family":"Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00fczeyyen","family":"Aslaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9417-6300","authenticated-orcid":false,"given":"\u015eermin","family":"Alt\u0131ndal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Arikan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Sinan","family":"Dal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5820-1903","authenticated-orcid":false,"given":"Burak","family":"Deveci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nil","family":"G\u00fcler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet K\u00fcr\u015fad","family":"G\u00fcne\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emel","family":"G\u00fcrkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9635-3091","authenticated-orcid":false,"given":"Demircan","family":"\u00d6zbalc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman Can","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"\u00dclk\u00fcden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fcseyin","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meltem Kurt","family":"Y\u00fcksel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meltem","family":"Ayl\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Muzaffer","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00fczg\u00fcn","family":"\u00d6zatl\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahir","family":"\u00d6zkalemka\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8646-1673","authenticated-orcid":false,"given":"G\u00fcray","family":"Saydam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"S\u00f6nmez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burhan","family":"Turgut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Turgut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7011-3412","authenticated-orcid":false,"given":"Ali","family":"\u00dcnal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9568-0894","authenticated-orcid":false,"given":"Ahmet Emre","family":"E\u015fkazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.leukres.2026.108239_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35953","article-title":"Management of chronic myeloid leukemia in 2025","volume":"131","author":"Kantarjian","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2026.108239_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106458","article-title":"The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase","volume":"98","author":"Manley","year":"2020","journal-title":"Leuk. Res"},{"issue":"24","key":"10.1016\/j.leukres.2026.108239_bib3","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N. Engl. J. Med"},{"issue":"5","key":"10.1016\/j.leukres.2026.108239_bib4","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s41375-023-01860-w","article-title":"Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results","volume":"37","author":"Mauro","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2026.108239_bib5","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000845700.84142.c0","article-title":"Asciminib provides durable molecular responses in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with the T315I mutation: updated eff\u0131cacy and safety data from a phase I trial","author":"Hughes","year":"2022","journal-title":"HemaSphere"},{"issue":"21","key":"10.1016\/j.leukres.2026.108239_bib6","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"R\u00e9a","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2026.108239_bib7","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","article-title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL","volume":"37","author":"Hochhaus","year":"2023","journal-title":"Leukemia"},{"issue":"36","key":"10.1016\/j.leukres.2026.108239_bib8","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.2217\/fon-2021-1174","article-title":"Asciminib as a new option in the treatment of chronic myeloid leukemia","volume":"17","author":"\u0130bi\u015f","year":"2021","journal-title":"Future Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2026.108239_bib9","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1002\/hon.70101","article-title":"Real-World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi-Resistant CML-CP Patient Population","volume":"43","author":"Breccia","year":"2025","journal-title":"Hematol. Oncol."},{"issue":"ement 1","key":"10.1016\/j.leukres.2026.108239_bib10","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1182\/blood-2023-181789","article-title":"The Updated Results of Asciminib Managed-Access Program (MAP) in Patients with Chronic Myeloid Leukemia in Russia","volume":"142","author":"Kuzmina","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2026.108239_bib11","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3324\/haematol.2022.281386","article-title":"Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population","volume":"108","author":"Kockerols","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2026.108239_bib12","doi-asserted-by":"crossref","first-page":"6796","DOI":"10.1182\/blood-2022-165501","article-title":"Real-world experience of asciminib: factors associated with response","volume":"140","author":"Innes","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2026.108239_bib13","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.leukres.2026.108239_bib14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41408-021-00420-8","article-title":"Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice","volume":"11","author":"Garcia-Guti\u00e9rrez","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2026.108239_bib15","first-page":"1","article-title":"Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia","author":"Chee","year":"2024","journal-title":"Intern Med J."},{"key":"10.1016\/j.leukres.2026.108239_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107374","article-title":"Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy","volume":"133","author":"Khadadah","year":"2023","journal-title":"Leuk. Res"},{"issue":"10","key":"10.1016\/j.leukres.2026.108239_bib17","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1007\/s00277-022-04932-6","article-title":"Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia","volume":"101","author":"Luna","year":"2022","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2026.108239_bib18","first-page":"1","article-title":"Clinical outcomes of patients with chronic myeloid leukemia with asciminib provided by a compassionate program in Brazil","author":"Pagnano","year":"2025","journal-title":"Blood Glob. Hematol."},{"issue":"4","key":"10.1016\/j.leukres.2026.108239_bib19","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3390\/cancers15041045","article-title":"Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors","volume":"15","author":"P\u00e9rez-Lamas","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.leukres.2026.108239_bib20","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1038\/s41375-024-02278-8","article-title":"Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after \u22651 prior tyrosine kinase inhibitor: 2-year follow-up results","volume":"38","author":"Cortes","year":"2024","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2026.108239_bib21","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/14740338.2024.2331190","article-title":"A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia","volume":"23","author":"\u00d6zmen","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"issue":"7","key":"10.1016\/j.leukres.2026.108239_bib22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/17474086.2017.1339599","article-title":"Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?","volume":"10","author":"Eskazan","year":"2017","journal-title":"Expert Rev. Hematol."},{"issue":"ement 1","key":"10.1016\/j.leukres.2026.108239_bib23","doi-asserted-by":"crossref","first-page":"7300","DOI":"10.1182\/blood-2025-7300","article-title":"Real-world data comparison of asciminib 40 mg twice daily vs. 80 mg once daily in chronic myeloid leukemia patients","volume":"146","author":"Pati\u00f1o","year":"2025","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.leukres.2026.108239_bib24","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1182\/blood-2023-187357","article-title":"Asciminib (ASC) Once-Daily (QD) Dosing Demonstrates Comparable Tolerability and Efficacy to Twice-Daily (BID) Dosing: Results from the ASC in Monotherapy 4 CML (AIM4CML) Study in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)","volume":"142","author":"Andorsky","year":"2023","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.leukres.2026.108239_bib25","doi-asserted-by":"crossref","first-page":"4526","DOI":"10.1182\/blood-2024-200017","volume":"144","author":"Hochhaus","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108239_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2025.108089","article-title":"Treatment with asciminib after a prior tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia","volume":"157","author":"Atallah","year":"2025","journal-title":"Leuk. Res"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:39:27Z","timestamp":1781051967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626000834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":26,"alternative-id":["S0145212626000834"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108239","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world data on the use of asciminib in chronic-phase chronic myeloid leukemia after two or more prior tyrosine kinase inhibitors: Results of the Turkish managed access program along with a literature review","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108239","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108239"}}